Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-

Similar documents
Comparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions

Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort

The Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology

Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)

3-year results of the OLIVE registry:

Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry

DCB in my practice: How the evidence influences my strategy. Yang-Jin Park

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Maximizing Outcomes in a complex population with Drug-coated balloon

2 Year Results from the MDT SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA

ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany

BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

Update from Korea on the Lutonix SFA registry 12 month data

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD

How do I use mechanical debulking for the treatment of arterial occlusions

12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany

The latest evidences from the DES trials in peripheral arterial disease

Wifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization

Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions

The essentials for BTK procedures: wires, balloons, what else

The Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD

Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report

2-YEAR DATA SUPERA POPLITEAL REAL WORLD

Clinical benefits on DES Patient s perspectives

Latest Insights from the LEVANT II study and sub-group analysis

Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?

Shockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany

The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan

DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

Drug-coated balloons in BTK:

Safety and Efficacy of Distal Superficial Femoral Artery Puncture for Femoropopliteal Occlusive Lesions

Drug- Coated Balloons for the SFA: Overview of Technology and Results

LIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:

Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD

Lessons learnt from DES in the SFA is there any ideal concept so far?

PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE

Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA

Accurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery

Preliminary 6-month results of VMI-CFA trial

Or is the ivolution stent a better alternative? EVOLUTION 12-month data

Atherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System

Importance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study

SAVER: Rationale and merits for an all-comers DCB e-registry Frank Vermassen MD

Dierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

Olive registry: 3-years outcome of BTK intervention in Japan. Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan

Adventitial Drug Infusion to Prevent Restenosis

Preliminary 12 Months results of the RAPID trial

TOBA Trial 12 months Results

Is a Stent or Scaffold Necessary in The SFA?

Drug-Eluting Balloon Angioplasty versus Bare Metal Stents for Femoropopliteal Disease in Real-World Experience

SFA CTO Lesion Management laser or directional atherectomy?

Adventitial Drug Therapy Below-the-Knee: Update on LIMBO and TANGO

Disclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA

The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium

Six Month Results of the Global BIOLUX P-III All-Comers Registry using Drug Coated Balloon in Infra-Inguinal Artery Disease

In-Stent Restenosis: New Evidence From Laser + Drug Coated Balloons

Klinikum Rosenheim Department of Diagnostic and Interventional Radiology

New Evidence from Laser + Drug Coated Balloons for Treatment of In-Stent Restenosis

Specificities for infrapopliteal stents

Update on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany

The incidence of peripheral artery disease (PAD)

Efficacy of DEB in Calcification and Subintimal Angioplasty

Update in femoral angioplasty & stenting PRO

One Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller

Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015

Update on the Ranger clinical trial programme

Intravascular Imaging Insights into the Mechanism of Action of Focal Force Balloon Angioplasty

Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results.

Treatment Strategies for Long Lesions of greater than 20 cm

COVERA covered stent to treat stenosis in arteriovenous fistula: 6-month results from the prospective, multi-center, randomized AVeNEW study

Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?

XPEDITE Clinical Study PaclitaXel-coated Peripheral StEnts used In the Treatment of FemoropoplitEal Stenoses

The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio

Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis

4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters

Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

The Supera stent In retrograde vascular access for SFA ostium treatment: The SUPRA-FAST Registry

Long-term Zilver PTX Data from Japan: 5-year Results in the Real World

January 23, Vascular and oncological interventional radiology Paris Descartes University

Extreme SFA Lesions: DETOUR I 12- Month Results in Lesions >30cm. Sean Lyden, MD Chairman Vascular Surgery Cleveland Clinic Cleveland, Ohio

Surgical Bypass or. Zilver PTX. 12 months preliminary data. LINC 2016, Leipzig. Marc Bosiers, MD. Marc Bosiers Koen Deloose Joren Callaert

Aggressive BTK Revascularization and Advanced Wound Care - Patient Specific Therapy Concepts

MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together

Update on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria

Atherectomy with thrombectomy of. Rotarex S : The Leipzig experience

ILLUMENATE FIH Direct DCB Cohort 12-Month Results

Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA

Brachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts

Successful endovascular treatment using biopsy forceps for iliac artery stenosis with an organized thrombus

PES BTK 70 : 12 m results with a paclitaxelcoated self-expanding stent in BTK arteries

Hybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case

Transcription:

Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis- Masahiko Fujihara Kishiwada Tokushukai Hospital, Osaka, Japan

Disclosure Speaker name : Mashiko Fujihara I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) I do not have any potential conflict of interest

Background Nitinol stent has been mainly used for the endovascular therapy (EVT) for superficial femoral artery disease (SFA) No detailed analysis of optimal balloon angioplasty was made in previous stent studies. Since the approval of drug-coated balloon (DCB), concept of nothing left behind is introduced However, definition of optimal balloon angioplasty are not clearly made and dissection pattern post balloon angioplasty are not reported

73 years old Male, R-2 Claudication Cutting Balloon 5x20mm Balloon 5x100mm

73 years old Male, R-2 Claudication Post balloon angioplasty IVUS Angioscopy

73 years old Male, R-2 Claudication 7 Months of Post balloon angioplasty

Aim Angiographic dissection pattern of post balloon angioplasty in SFA lesions were evaluated The clinical outcome of balloon alone procedure based on dissection pattern were examined

Material and Method Study Design A retrospective, multicenter, non randomized investigation at 4 cardiovascular centers Inclusion criteria Exclusion Criteria Age >20 years old Rutherford category class (RCC) 2 6 Angiographic evaluation was performed post balloon angioplasty In SFA stent restenosis Direct SFA stent CO2 Angiography Drug coated balloon Participated Hospital Kishiwada Tokushukai Hospital Kansai Rosai Hospital Saka General Hospital Tokyo Rosai Hospital Journal of Endovascular Therapy in Press

STUDY Scheme and Endpoints 748 PAOD patients with symptomatic SFA lesions Bare Balloon Angioplasty Dissection pattern Balloon Alone Procedure N=193 Bailout Stent Implantation N=555 Analysis of Clinical outcome (Patency and TLR)

Definition of Vessel Dissection A B C D E F

Patient and Lesion Characteristics All N=748 All N=748 Age (years old) 72.6± 9.5 Lesion Length (mm) 148.1±92.4 Male (%) 66.8 Ref vessel size (mm) 5.4±1.0 Hypertension(%) 88.2 TASC CD (%) 46.5 Diabetes (%) 58.4 CTO (%) 40.2 Dyslipidemia (%) 52.6 Calcification Obesity(%) 14.0 None 34.8 Regular Hemodialysis (%) 32.7 Moderate 26.6 Coronary Artery Disease (%) 63.2 Severe 38.6 Critical Limb Ischemia (%) 35.0 Non BTK run-off 15.8 Rutherford Classification 3.50±1.2

Procedure Characteristics All N=748 Bare Balloon (%) 97.6 Cutting Balloon (%) 2.4 Balloon Type 0.014 inch (%) 21.2 0.018 inch (%) 63.1 0.035 inch (%) 15.6 Balloon Size Average Balloon size 4.7±0.8 Balloon size 5mm (%) 62.7 Average Inflation time (sec) 80.7±88 Inflation Time 2minutes (%) 30.7 IVUS use (%) 27.8

Dissection Pattern of Post Balloon Angioplasty C to F 40% D 24% E 9% F 6% None 13% A 24% None A and B 60% C 9% B 26%

Stent 87% POBA Stent Implantation rate between Dissection Pattern Stent 90% D Stent POBA 82% C E F POBA Stent None B Stent 57% 94% Primary or Stent 74% A POBA Stent 60% POBA Bailout Stent Implantation rate 74.1% Balloon Alone Procedure 25.8%

Hazard ratio for restenosis Hazard Ratio of restenosis comparison with dissection pattern 1000 100 10 No Severe Dissection Severe Dissection HR [95% CI] (p value) None 1.58 [0.79, 3.16] (p = 0.193) A 1.00 (Ref) B 1.81 [0.88, 3.73] (p = 0.108) 1 C 4.45 [1.22, 16.2] (p = 0.024) D 6.37 [2.99, 13.6] (p< 0.001) 0 None A B C D E F Dissection type E 22.9 [7.33, 71.6] (p< 0.001) F 297 [34.9, 2527] (p< 0.001) Data are unadjusted hazard ratios for restenosis relative to type A dissection, obtained from the Cox regression model with mixed effects, in which inter-subject variability was treated as random effects. Error bars indicate 95% confidence intervals. *Statistical analysis was performed by R version 3.1.0 (R Core Team, Vienna, Austria).

Clinical Outcomes of Balloon Alone Procedure Primary Patency (PSVR<2.5) p < 0.001 log-rank Non severe Dissection Free from Clinically Driven TLR p < 0.001 log-rank Non severe dissection Severe Dissection Severe Dissection Follow up period (days) Days 0 180 360 540 720 at risks (Category-1) 155 113 67 41 30 % 100 81 65 58 53 at risks (Category-2) 38 14 5 2 2 % 100 38 11 7 7 Follow up period (days) Days 0 180 360 540 720 at risks (Category-1) 155 118 78 47 33 % 100 86 75 67 62 at risks (Category-2) 38 20 8 6 3 % 100 66 34 30 15

Predictive factors for Severe dissection - Multivariate analysis Uni- Severe Dissection (Type C,D and F) Multivariate P value HR 95%CI P Value Non Hemodialysis 0.0159 1.09 0.74-1.63 0.64 CTO <0.0001 4.3 3.02-6.4 <0.001* TASC CD <0.0001 2.1 1.46-3.06 <0.001* Reference vessel diameter<5mm <0.0001 1.94 1.25-3.04 0.0032* Non Severe Calc 0.0308 1.38 0.95-2.02 0.08 Large inch system balloon (0.035inch) 0.0080 1.60 0.97-2.67 0.06 Vessel/balloon size<1.0 0.0004 1.28 0.76-2.15 0.34 IVUS usage 0.013 1.55 1.06-2.27 0.021*

Prevalence of severe dissection TASC CD and small vessel were strong predictor of severe dissection 100% 80% 60% 40% 20% 0% class D class C class B TASC II classification class A < 5 5 to 6 6 Data are prevalence of severe dissection in subgroups, calculated from the generalized linear mixed model with logit-link function, in which inter-subject variability was treated as random effects. *Statistical analysis was performed by R version 3.1.0 (R Core Team, Vienna, Austria).

Conclusions Angiographic dissection pattern of post balloon angioplasty in SFA lesions were analyzed 42 % of cases resulted in C, D, E and F type severe dissection. Primary patency rate and freedom from clinically driven TLR rate were significantly lower in severe dissection The predictive factors of severe dissection were found in TASC(ll) CD, small vessel and total occlusion. Calcified lesion was not predictive factor. In case of severe dissection, balloon alone procedure has the limitation in regards to restenosis and CD-TLR